Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06859710 · ClinicalTrials.gov registry record · Phase 1
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
A Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06859710: Recruiting Phase 1 study of Pain and Abuse, Drug, sponsored by University of California, Los Angeles.
NCT06859710 is a Phase 1 study of Pain and Abuse, Drug that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06859710, a Phase 1 study of Pain and Abuse, Drug, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess the impact of CBD on the effects of THC.
Primary Outcome
Subject ratings of "Good Drug Effect" as measured using a visual analog scale (1-100 mm)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG THC
- DRUG CBD 20 mg
- DRUG CBD 40 mg
- DRUG CBD 80 mg
Study Locations (1)
California
- UCLA Center for Cannabis and Cannabinoids - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 1 |
What NCT06859710 shows while recruiting
NCT06859710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06859710 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06859710 about?
NCT06859710 is a clinical study titled "THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy". The purpose of this research is to assess the impact of CBD on the effects of THC.
What is the current status of trial NCT06859710?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-05. Estimated completion is 2028-09-01.
What conditions does trial NCT06859710 study?
This clinical trial studies the following conditions: Pain, Abuse, Drug.
What interventions are being tested in trial NCT06859710?
The interventions under investigation include: Placebo (DRUG), THC (DRUG), CBD 20 mg (DRUG), CBD 40 mg (DRUG), CBD 80 mg (DRUG).
Who is sponsoring clinical trial NCT06859710?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06859710 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06859710's enrollment target sits among peer trials
30 310th of 374 higher than 60 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
-
Age-dependent Effects of Smoked and Oral Delta-9-THC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI